BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In a phase I trial of ruxolitinib in combination with nilotinib in patients with CML-CP, a reduction in phosphorylated-STAT3 was observed after treatment, and 10 (40%) patients had undetectable BCR-ABL1 transcripts [111].